Results

#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial

So far this year Allogene has barreled out of left field with a pair of the most experienced CAR-T execs in the industry steering the new business to a record-setting (for now) IPO. And they’re headed straight into their first update on data for what an off-the-shelf CAR-T can do for patients suffering from acute lymphoblastic leukemia — with what they believe is a manageable safety profile.

Still tinkering with what they envision is just the right kind of edited CAR-T for the work, their UCART19 program — picked up from Pfizer and partnered with Cellectis — produced some promising proof-of-concept results on the first 21 patient results pooled from two small studies. Fourteen out of 17 pre-treated with a standard flu/cy lymphodepletion regimen plus an immunosuppressing therapy achieved a complete response with significant cell expansion.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 35,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->